Author

Didier Leroy

Medicines for Malaria VentureORCID 0000-0002-5594-3204Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:plant (other)· 2 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Christin GumppiD· 3 shared Matthias RottmanniD· 3 shared Maëlle DuffeyiD· 2 shared Nicolas M. B. BrancucciiD· 2 shared Andrew M. BlagboroughiD· 1 shared Angela HellingmaniD· 1 shared Armin PasseckeriD· 1 shared Artur ScherfiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

Christin GumppORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

MicrobiologybioRxivPreprintJul 28, 2026

Multidimensional in vitro assay for antimalarial combination testing and pharmacodynamic modeling - the MULT-i2 assay

Angela Hellingman, Christin Gumpp, Jörg J. Möhrle…·Matthias Rottmann

The paper introduces a high-throughput in vitro assay for evaluating antimalarial drug combinations and their pharmacodynamic interactions, showing improved efficiency and resolution compared to existing methods.

DOI 10.64898/2026.05.06.723157

plant (other)experimental assay

𝕏 PostBluesky

MicrobiologybioRxivPreprintMar 3, 2026

Comparing the transmission blocking efficacy of Primaquine and Tafenoquine with in vivo pre-clinical models

Maëlle Duffey, Sara E. Zakutansky, Christin Gumpp…·Andrew M. Blagborough

This study compares the transmission blocking efficacy of primaquine and tafenoquine in vivo, finding tafenoquine more effective due to better pharmacokinetics beyond 24 hours.

DOI 10.64898/2026.03.03.709295

experimental assayhost-pathogen & immune response

𝕏 PostBluesky

MicrobiologyNature CommunicationsPeer-reviewedJul 25, 2025

An all-in-one pipeline for the in vitro discovery and in vivo testing of Plasmodium falciparum malaria transmission blocking drugs

Nicolas M. B. Brancucci, Christin Gumpp, Geert‐Jan van Gemert…·Till Steffen Voss

The paper develops an in vitro and in vivo platform for testing malaria transmission-blocking drugs using engineered Plasmodium falciparum gametocytes and humanized mice.

8 citationstop 3%

humanmouse

𝕏 PostBluesky